http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#Head http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#assertion http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#provenance http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#pubinfo http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#assertion http://purl.obolibrary.org/obo/DOID_5844 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_5844 http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00540 http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#association http://www.w3.org/2000/01/rdf-schema#label "The use of nortriptyline hydrochloride or other tricyclic antidepressants concurrently with a monoamine oxidase (MAO) inhibitor is contraindicated. Hyperpyretic crises, severe convulsions, and fatalities have occurred when similar tricyclic antidepressants were used in such combinations. It is advisable to have discontinued the MAO inhibitor for at least two weeks before treatment with nortriptyline hydrochloride is started. Patients hypersensitive to nortriptyline hydrochloride should not be given the drug. Cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. Nortriptyline hydrochloride is contraindicated during the acute recovery period after myocardial infarction." http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#association https://w3id.org/biolink/vocab/relation https://schema.org/MedicalContraindication https://identifiers.org/drugbank:DB00540 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#provenance http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#pubinfo http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#sig http://purl.org/nanopub/x/hasSignature HXF0YGLD/NCgn1AN0B4WB7SzzBQsc8xxY4td3e4BGxyjPuqrwFWf1J5yAHTjjoPHWbAPOK0jKYQUlnDiMVNW4NykzdOFsAPC0xK30UCxtbFFjG/wEUoc75sNJmWfbhI6YmIwuCE95BW5jHZw2dvWtd11cNz0S0mcTQGPUizXDVQ= http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw http://purl.org/dc/terms/created 2021-08-25T13:35:57.634+02:00 http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAfNk_vtkgfTN1wVNVBeoKLyvM9SrbwBP42b1cO0x6vYw https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY